Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Eyes shut homolog (EYS) is a large secreted protein that contains multiple epidermal growth factor (EGF)-like domains and laminin G-like domains[1][2][3]. EYS is predominantly expressed in retinal photoreceptor cells and is essential for the organization and maintenance of photoreceptor cell structure, in particular the interphotoreceptor matrix and the connecting cilium, which is crucial for protein trafficking in the retina[3][4]. It is closely related to invertebrate proteins involved in compartmentalization of sensory epithelia. EYS interacts with the carbohydrate matriglycan through its LG domains, supporting photoreceptor survival[2]. Mutations in EYS are among the most frequent genetic causes of autosomal recessive retinitis pigmentosa, and can also cause cone-rod dystrophy[1][2][3][4]. The EYS gene is one of the largest human genes, with 44–46 exons and encoding a protein of approximately 3000 amino acids[1][3]. Loss of EYS function leads to disorganized retinal architecture and progressive visual impairment, but there are currently no approved drugs directly targeting EYS[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Eyes shut homolog (EYS).